Helicobacter pylori infection natural history, complications and prognosis
Jump to navigation
Jump to search
|
Helicobacter pylori infection Microchapters |
|
Differentiating Helicobacter pylori infection from other Diseases |
|---|
|
Diagnosis |
|
Guideline Recommendation |
|
Treatment |
|
Case Studies |
|
Helicobacter pylori infection natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Helicobacter pylori infection natural history, complications and prognosis |
|
FDA on Helicobacter pylori infection natural history, complications and prognosis |
|
CDC on Helicobacter pylori infection natural history, complications and prognosis |
|
Helicobacter pylori infection natural history, complications and prognosis in the news |
|
Blogs on Helicobacter pylori infection natural history, complications and prognosis |
|
Directions to Hospitals Treating Helicobacter pylori infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Yamuna Kondapally, M.B.B.S[3]
Overview
H. pylori infection is usually acquired in childhood and, if it is not treated, persists for life. Almost every colonized person develops chronic active gastritis, although most remain asymptomatic.[1][2] The pattern of gastritis largely determines the long-term outcome:
- Antral-predominant gastritis predisposes to duodenal ulcer.
- Corpus-predominant or atrophic gastritis predisposes to gastric ulcer, intestinal metaplasia, and non-cardia gastric adenocarcinoma.[3]
The major complications are peptic ulcer disease (lifetime risk about 10–20%), distal gastric adenocarcinoma (about 1–2%), and gastric MALT lymphoma (<1%).[4] Overall prognosis is favorable. Confirmed eradication cures most ulcer disease, lowers gastric cancer incidence and mortality, and induces remission in most patients with early-stage gastric MALT lymphoma. Residual cancer risk persists when atrophy or intestinal metaplasia is already established.[5][6]
Natural History
Acquisition and Persistence
- Most infections are acquired in childhood (usually before age 10) and persist throughout life without spontaneous clearance in adults.[1]
- Acute infection is almost never recognized clinically. It is followed by chronic active gastritis in virtually all persistently colonized persons.[3]
- Chronic gastritis stays asymptomatic for decades in most people. Only a minority develop clinically significant disease, depending on:
Gastritis Phenotype Determines Outcome
| Gastritis pattern | Acid secretion | Principal sequelae |
|---|---|---|
| Antral-predominant, non-atrophic | Normal or increased | Duodenal ulcer |
| Corpus-predominant or multifocal atrophic | Decreased (hypochlorhydria → achlorhydria) | Gastric ulcer, gastric atrophy, intestinal metaplasia, dysplasia, gastric adenocarcinoma |
Progression to Gastric Adenocarcinoma (Correa Cascade)
- Intestinal-type gastric adenocarcinoma develops through a multistep sequence:
- non-atrophic chronic gastritis
- atrophic gastritis
- intestinal metaplasia
- dysplasia
- invasive adenocarcinoma[1]
- In a prospective Japanese cohort of 1,526 patients followed with serial endoscopy:[7]
- Gastric cancer developed in 2.9% of infected patients and in none of the uninfected patients.
- Severe atrophy, corpus-predominant gastritis, and intestinal metaplasia identified the highest-risk patients.
- Patients with duodenal ulcer did not develop gastric cancer.
- In a U.S. Veterans Affairs cohort of 371,813 infected patients, cumulative incidence of non-proximal gastric adenocarcinoma after detection of H. pylori was:[8]
- 0.37% at 5 years
- 0.50% at 10 years
- 0.65% at 20 years
Complications
| Complication | Approximate risk in infected persons | Effect of eradication |
|---|---|---|
| Peptic ulcer disease (gastric and duodenal) | Lifetime risk about 10–20%[4] | Heals ulcers and markedly reduces recurrence[2] |
| Non-cardia gastric adenocarcinoma | Lifetime risk about 1–2%[4] | Lowers incidence and mortality; benefit is greatest before atrophy or metaplasia develops[5][6] |
| Gastric MALT lymphoma | <1%[4] | Remission in about 75% of early-stage, H. pylori–positive cases[9] |
Peptic Ulcer Disease
- H. pylori remains a leading cause of gastric and duodenal ulcers, and eradication heals ulcers and prevents recurrence.[2]
- NSAIDs are an independent and often coexisting cause, so both should be evaluated in every ulcer patient.[2]
- Ulcer complications (bleeding, perforation, gastric outlet obstruction) are the main source of acute morbidity from untreated infection.[1]
Gastric Adenocarcinoma
- H. pylori is classified by the WHO International Agency for Research on Cancer as a group 1 (definite) carcinogen.[2]
- It is the strongest known risk factor for non-cardia gastric adenocarcinoma and accounts for the large majority of these cancers.[1][2]
- Among infected U.S. veterans, risk of future gastric cancer was higher with:[8]
- older age
- racial and ethnic minority groups
- smoking
- H. pylori is associated with both intestinal-type and diffuse-type adenocarcinoma.[1]
Gastric MALT Lymphoma
- Gastric mucosa-associated lymphoid tissue lymphoma is a low-grade extranodal marginal zone B-cell lymphoma driven by chronic H. pylori–induced lymphoid proliferation.[1]
- Eradication is the recognized initial therapy for early-stage, H. pylori–positive disease and achieves remission in about 75% of patients.[9]
Premalignant Gastric Conditions
- Chronic infection drives atrophic gastritis and intestinal metaplasia, the precursor lesions of intestinal-type adenocarcinoma.[1]
- Severe or extensive (corpus-involving) metaplasia and dysplasia carry the highest risk.[7]
- Endoscopic surveillance (often about every 3 years) is suggested for individuals with high-risk intestinal metaplasia or dysplasia, and for those with resected dysplasia or early cancer.[10]
Extragastric Complications
- Iron-deficiency anemia: H. pylori is an established cause of unexplained or refractory iron deficiency anemia.[1][11]
- Vitamin B12 deficiency: Atrophic corpus gastritis with achlorhydria can impair B12 absorption.[1]
- Immune thrombocytopenic purpura: ITP is an established extragastric association.[1][11]
Prognosis
Untreated Infection
- Most infected individuals remain asymptomatic lifelong.
- Lifetime risks are about:[4]
- 10–20% for ulcer disease
- 1–2% for distal gastric cancer
- <1% for MALT lymphoma
- Gastric cancer risk is concentrated in patients with:[7]
- corpus-predominant atrophic gastritis
- intestinal metaplasia
- dysplasia
Prognostic Modifiers
- Confirmed cure is required. Cancer-risk reduction depends on documented eradication. Post-treatment test-of-cure (urea breath test, stool antigen, or biopsy-based testing) at least 4 weeks after therapy is recommended for all treated patients.[8][11]
- Timing of eradication. Benefit is greatest when eradication precedes atrophy and intestinal metaplasia. Once these changes are established, residual cancer risk persists, so continued endoscopic surveillance is needed in high-risk mucosa.[6][10]
- Latency of benefit. The cancer-prevention effect is delayed by years and is not evident in short-term follow-up.[12]
- Generalizability. Most randomized evidence comes from high-incidence East Asian populations; Western prospective trial data are limited.[5][6]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, Smith SI, Suerbaum S (2023). "Helicobacter pylori infection". Nat Rev Dis Primers. 9 (1): 19. doi:10.1038/s41572-023-00431-8. PMID 37081005 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Crowe SE (2019). "Helicobacter pylori infection". N Engl J Med. 380 (12): 1158–1165. doi:10.1056/NEJMcp1710945. PMID 30893536.
- ↑ 3.0 3.1 3.2 Suerbaum S, Michetti P (2002). "Helicobacter pylori infection". N Engl J Med. 347 (15): 1175–86. doi:10.1056/NEJMra020542. PMID 12374879.
- ↑ 4.0 4.1 4.2 4.3 4.4 Kusters JG, van Vliet AH, Kuipers EJ (2006). "Pathogenesis of Helicobacter pylori infection". Clin Microbiol Rev. 19 (3): 449–90. doi:10.1128/CMR.00054-05. PMC 1539101. PMID 16847081.
- ↑ 5.0 5.1 5.2 Ford AC, Yuan Y, Moayyedi P (2020). "Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis". Gut. 69 (12): 2113–2121. doi:10.1136/gutjnl-2020-320839. PMID 32205420 Check
|pmid=value (help). - ↑ 6.0 6.1 6.2 6.3 Moss SF, Shah SC, Tan MC, El-Serag HB (2024). "Evolving concepts in Helicobacter pylori management". Gastroenterology. 166 (2): 267–283. doi:10.1053/j.gastro.2023.09.047. PMID 37806461 Check
|pmid=value (help). - ↑ 7.0 7.1 7.2 Uemura N, Okamoto S, Yamamoto S; et al. (2001). "Helicobacter pylori infection and the development of gastric cancer". N Engl J Med. 345 (11): 784–9. doi:10.1056/NEJMoa001999. PMID 11556297.
- ↑ 8.0 8.1 8.2 Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS (2020). "Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study". Gastroenterology. 158 (3): 527–536.e7. doi:10.1053/j.gastro.2019.10.019. PMID 31654635.
- ↑ 9.0 9.1 Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D (2010). "Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma". Clin Gastroenterol Hepatol. 8 (2): 105–10. doi:10.1016/j.cgh.2009.07.017.
- ↑ 10.0 10.1 Shah SC, Wang AY, Wallace MB, Hwang JH (2025). "AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: expert review". Gastroenterology. PMID 39718517 Check
|pmid=value (help). - ↑ 11.0 11.1 11.2 Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, Shah SC (2024). "ACG clinical guideline: treatment of Helicobacter pylori infection". Am J Gastroenterol. 119 (9): 1730–1753. doi:10.14309/ajg.0000000000002968. PMID 39626064 Check
|pmid=value (help). - ↑ Invalid
<ref>tag; no text was provided for refs namedLi2023